Robert Driscoll
Stock Analyst at Wedbush
(1.23)
# 3,271
Out of 4,810 analysts
157
Total ratings
27.34%
Success rate
-13.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.27 | +214.96% | 10 | Mar 28, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $4.43 | +283.75% | 4 | Mar 21, 2025 | |
| HOWL Werewolf Therapeutics | Reiterates: Outperform | $8 | $0.86 | +832.62% | 2 | Mar 12, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $7.58 | +58.31% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $7.19 | +345.06% | 6 | Feb 26, 2025 | |
| KURA Kura Oncology | Maintains: Outperform | $34 → $36 | $6.03 | +497.01% | 8 | Feb 6, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $16.98 | +206.24% | 9 | Dec 17, 2024 | |
| RVMD Revolution Medicines | Maintains: Outperform | $70 → $67 | $36.32 | +84.47% | 4 | Dec 6, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $8.66 | +223.33% | 8 | Oct 25, 2024 | |
| BDTX Black Diamond Therapeutics | Reiterates: Outperform | $16 | $1.42 | +1,026.76% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $8.01 | +274.53% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $1.27 | +1,632.28% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $51 | $5.99 | +751.42% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.59 | +745.17% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $7.80 | +361.54% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.58 | +596.20% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $3.57 | +264.15% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $1.38 | +845.45% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $29.06 | +154.65% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.70 | +370.59% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.25 | +460.00% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $0.63 | +1,166.83% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $0.31 | +2,451.83% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $7.71 | +574.45% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.16 | +26.58% | 4 | May 19, 2020 |
Zentalis Pharmaceuticals
Mar 28, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.27
Upside: +214.96%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $4.43
Upside: +283.75%
Werewolf Therapeutics
Mar 12, 2025
Reiterates: Outperform
Price Target: $8
Current: $0.86
Upside: +832.62%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $7.58
Upside: +58.31%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $7.19
Upside: +345.06%
Kura Oncology
Feb 6, 2025
Maintains: Outperform
Price Target: $34 → $36
Current: $6.03
Upside: +497.01%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $16.98
Upside: +206.24%
Revolution Medicines
Dec 6, 2024
Maintains: Outperform
Price Target: $70 → $67
Current: $36.32
Upside: +84.47%
Tyra Biosciences
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $8.66
Upside: +223.33%
Black Diamond Therapeutics
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $1.42
Upside: +1,026.76%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $8.01
Upside: +274.53%
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $1.27
Upside: +1,632.28%
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $5.99
Upside: +751.42%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.59
Upside: +745.17%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $7.80
Upside: +361.54%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.58
Upside: +596.20%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $3.57
Upside: +264.15%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $1.38
Upside: +845.45%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $29.06
Upside: +154.65%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.70
Upside: +370.59%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.25
Upside: +460.00%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $0.63
Upside: +1,166.83%
May 3, 2024
Reiterates: Outperform
Price Target: $8
Current: $0.31
Upside: +2,451.83%
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $7.71
Upside: +574.45%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.16
Upside: +26.58%